Propanc Receives Investment to Initiate GLP Safety Toxicology Study for PRP

Set to Initiate Development and GMP manufacture of Finished Drug Product for
First-In-Man Studies

PR Newswire

MELBOURNE, Australia, July 5, 2016

MELBOURNE, Australia, July 5, 2016 /PRNewswire/ -- Propanc Health Group
Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare
company focusing on development of new and proprietary treatments for cancer
patients suffering from solid tumors such as pancreatic, ovarian and
colorectal cancers, today announced the Company executed a Letter Agreement
with an institutional investor resulting in the Company receiving $314,286 in
order to progress their lead product, PRP, towards first-in-man studies.

Life-changing Biotech

The cash provides sufficient capital to support research and development
activities including commencement of the in-life phase of a formal 28 day
toxicology study (including a toxicokinetic arm designed to determine the
relationship between the level of exposure of PRP in the blood and its
toxicity) according to GLP (Good Laboratory Practice) standard, method
validation of an IR (infrared) dye-labelling method for analyzing the
metabolism and distribution of PRP in blood plasma, as well as corporate and
administrative expenses.

The Company is also presently negotiating with a contract manufacturer
development and GMP (Good Manufacturing Practice) manufacture of finished drug
product for PRP to be used for first-in-man studies, and expects to commence
this phase of development soon.

"We continue to receive support from our lead investor, who understands the
needs of our business, as we invest a significant amount of our capital into
development of our lead product, PRP, towards first-in-man studies," said
James Nathanielsz, Propanc's Chief Executive Officer. "I am pleased to say we
are on track and executing our plans, which we believe could unlock
significant value for the Company and its shareholders in the near future."

The Company aims to fast track the development of proenzyme related oncology
products into clinical trials initially for pancreatic and ovarian cancers,
followed by colorectal cancer. According to Global Analyst Reports, the
combined world market for pancreatic, ovarian and colorectal cancers are
expected to reach over $12 billion by 2020.

As further described in the Company's Current Report on Form 8-K filed with
the Securities and Exchange Commission on July 5, 2016, the Company and the
institutional investor entered into a Letter Agreement on July 1, 2016, where
the parties adjusted the terms of an existing securities purchase agreement.
The Letter Agreement resulted in the exercise of an outstanding common stock
purchase warrant held by the institutional investor for cash consideration to
the Company of $314,286, in exchange for a reduction in the exercise price per
share. The terms of the securities purchase agreement and common stock
purchase warrant were previously disclosed in the Company's Current Report on
Form 8-K filed with the Securities and Exchange Commission on November 3,

About Propanc:
Propanc is developing new cancer treatments for patients suffering from
pancreatic, ovarian and colorectal cancers. We have developed a formulation of
anti-cancer compounds, which exert a number of effects designed to control or
prevent tumors from recurring and spreading throughout the body. Our products
involve or employ pancreatic proenzymes, which are inactive precursors of

In the near term, we intend to target patients with limited remaining
therapeutic options for the treatment of solid tumors. In future, we intend to
develop our lead product to treat (i) early stage cancer and (ii)
pre-cancerous diseases and (iii) as a preventative measure for patients at
risk of developing cancer based on genetic screening.  For more information,

Forward-looking Statements:

All statements other than statements of historical fact contained herein are
"forward-looking statements" for purposes of federal and state securities
laws. Forward-looking statements may include the words "may," "will,"
"estimate," "intend," "continue," "believe," "expect," "plan" or "anticipate"
and other similar words. Although we believe that the expectations reflected
in our forward-looking statements are reasonable, actual results could differ
materially from those projected or assumed. Our future financial condition and
results of operations, as well as any forward-looking statements, are subject
to change and to inherent risks and uncertainties including those regarding
our earnings, revenues and financial condition, our ability to implement our
plans, strategies and objectives for future operations, our ability to execute
on proposed new products, services or development thereof, our ability to
establish and maintain the proprietary nature of our technology through the
patent process, our ability to license from others patents and patent
applications, if necessary, to develop certain products, our ability to
implement our long range business plan for various applications of our
technology, our ability to enter into agreements with any necessary
manufacturing, marketing and/or distribution partners for purposes of
commercialization, the results of our clinical research and development,
competition in the industry in which we operate, overall market conditions,
and any statements or assumptions underlying any of the foregoing. Other
risks, uncertainties and factors that could cause actual results to differ
materially from those projected may be described from time to time in reports
we file with the Securities and Exchange Commission, including our reports on
Forms 10-K, 10-Q and 8-K. We do not intend, and undertake no obligation, to
update any forward-looking statement contained herein, except as required by

This is not a solicitation to buy or sell securities and does not purport to
be an analysis of the company's financial position.

Logo -

To view the original version on PR Newswire,

SOURCE Propanc Health Group Corporation

Contact: Stanley Wunderlich, Consulting for Strategic Growth 1 Ltd, CEO,
800-625-2236 ext. 7770,, 880 Third Ave (53rd Street),
6th Floor, New York, NY, 10022,